Karyopharm Therapeutics (KPTI) Competitors

$7.14 -0.53 (-6.91%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$7.15 +0.01 (+0.14%)

As of 05:35 AM Eastern

KPTI vs. ANRO, RLMD, AVTE, GYRE, and SLDB

Should you buy Karyopharm Therapeutics stock or one of its competitors? MarketBeat compares Karyopharm Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Karyopharm Therapeutics include Alto Neuroscience (ANRO), Relmada Therapeutics (RLMD), Aerovate Therapeutics (AVTE), Gyre Therapeutics (GYRE), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.

How does Karyopharm Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 5 mentions for Alto Neuroscience. Karyopharm Therapeutics' average media sentiment score of 0.39 beat Alto Neuroscience's score of -0.07 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Karyopharm Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Alto Neuroscience has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Alto Neuroscience has higher earnings, but lower revenue than Karyopharm Therapeutics. Alto Neuroscience is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Karyopharm Therapeutics	$146.07M	1.11	-$196.04M	-$15.09	N/A

Alto Neuroscience has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Alto Neuroscience currently has a consensus price target of $35.25, indicating a potential upside of 61.41%. Karyopharm Therapeutics has a consensus price target of $17.17, indicating a potential upside of 140.43%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

66.4% of Karyopharm Therapeutics shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Karyopharm Therapeutics beats Alto Neuroscience on 9 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Relmada Therapeutics has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Relmada Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Karyopharm Therapeutics	$146.07M	1.11	-$196.04M	-$15.09	N/A

In the previous week, Relmada Therapeutics and Relmada Therapeutics both had 7 articles in the media. Karyopharm Therapeutics' average media sentiment score of 0.39 beat Relmada Therapeutics' score of 0.10 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Karyopharm Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Relmada Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Relmada Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 89.27%. Karyopharm Therapeutics has a consensus target price of $17.17, suggesting a potential upside of 140.43%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Karyopharm Therapeutics beats Relmada Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Aerovate Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

66.4% of Karyopharm Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Karyopharm Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

In the previous week, Karyopharm Therapeutics had 7 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 0 mentions for Aerovate Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.39 beat Aerovate Therapeutics' score of 0.00 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
Aerovate Therapeutics	Neutral

Aerovate Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Karyopharm Therapeutics currently has a consensus target price of $17.17, suggesting a potential upside of 140.43%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Karyopharm Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aerovate Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.11	-$196.04M	-$15.09	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Summary

Karyopharm Therapeutics beats Aerovate Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Gyre Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Karyopharm Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market.

Karyopharm Therapeutics currently has a consensus price target of $17.17, indicating a potential upside of 140.43%. Gyre Therapeutics has a consensus price target of $17.00, indicating a potential upside of 163.98%. Given Gyre Therapeutics' higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 10.0% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 6 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.08 beat Karyopharm Therapeutics' score of 0.39 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Gyre Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.11	-$196.04M	-$15.09	N/A
Gyre Therapeutics	$116.59M	5.36	$5.03M	-$0.09	N/A

Gyre Therapeutics has a net margin of -5.44% compared to Karyopharm Therapeutics' net margin of -129.02%. Gyre Therapeutics' return on equity of 3.13% beat Karyopharm Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Summary

Gyre Therapeutics beats Karyopharm Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Solid Biosciences and Solid Biosciences both had 7 articles in the media. Karyopharm Therapeutics' average media sentiment score of 0.39 beat Solid Biosciences' score of -0.14 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Karyopharm Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 13.6% of Solid Biosciences shares are held by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Solid Biosciences has higher earnings, but lower revenue than Karyopharm Therapeutics. Solid Biosciences is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Karyopharm Therapeutics	$146.07M	1.11	-$196.04M	-$15.09	N/A

Solid Biosciences has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Solid Biosciences has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Solid Biosciences presently has a consensus target price of $16.36, indicating a potential upside of 151.36%. Karyopharm Therapeutics has a consensus target price of $17.17, indicating a potential upside of 140.43%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Solid Biosciences is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Solid Biosciences beats Karyopharm Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPTI vs. The Competition

Export

Metric	Karyopharm Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$173.82M	$3.00B	$6.25B	$12.29B
Dividend Yield	N/A	1.98%	2.80%	5.32%
P/E Ratio	-0.47	17.22	20.64	25.23
Price / Sales	1.11	286.32	554.85	79.36
Price / Cash	N/A	56.35	27.48	37.30
Price / Book	-0.45	3.93	9.66	6.63
Net Income	-$196.04M	$74.99M	$3.56B	$335.59M
7 Day Performance	-19.87%	-4.47%	-1.65%	-1.20%
1 Month Performance	-17.07%	-7.93%	-2.60%	-1.16%
1 Year Performance	39.18%	29.34%	30.07%	28.10%

Karyopharm Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPTI Karyopharm Therapeutics	3.2592 of 5 stars	$7.14 -6.9%	$17.17 +140.4%	+34.2%	$173.82M	$146.07M	N/A	380	Earnings Report
ANRO Alto Neuroscience	2.61 of 5 stars	$24.44 +0.7%	$35.13 +43.7%	+756.1%	$775M	N/A	N/A	N/A	Earnings Report Analyst Downgrade
RLMD Relmada Therapeutics	2.8046 of 5 stars	$7.36 +0.5%	$12.00 +63.0%	+1,275.3%	$767.78M	N/A	N/A	10	Earnings Report
AVTE Aerovate Therapeutics	N/A	$25.81 +6.6%	N/A	+218.0%	$748.10M	N/A	N/A	20	Gap Down High Trading Volume
GYRE Gyre Therapeutics	2.9368 of 5 stars	$7.09 -5.1%	$17.00 +139.8%	-43.3%	$724.54M	$116.59M	N/A	40	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPTI) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. ANRO, RLMD, AVTE, GYRE, and SLDB

How does Karyopharm Therapeutics compare to Alto Neuroscience?

Summary

How does Karyopharm Therapeutics compare to Relmada Therapeutics?

Summary

How does Karyopharm Therapeutics compare to Aerovate Therapeutics?

Summary

How does Karyopharm Therapeutics compare to Gyre Therapeutics?

Summary

How does Karyopharm Therapeutics compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. ANRO, RLMD, AVTE, GYRE, and SLDB

How does Karyopharm Therapeutics compare to Alto Neuroscience?

Does the media favor ANRO or KPTI?

Is ANRO or KPTI more profitable?

Which has better earnings & valuation, ANRO or KPTI?

Which has more volatility and risk, ANRO or KPTI?

Do analysts prefer ANRO or KPTI?

Do institutionals and insiders hold more shares of ANRO or KPTI?

Summary

How does Karyopharm Therapeutics compare to Relmada Therapeutics?

Which has more risk & volatility, RLMD or KPTI?

Which has preferable earnings & valuation, RLMD or KPTI?

Does the media favor RLMD or KPTI?

Is RLMD or KPTI more profitable?

Do institutionals and insiders hold more shares of RLMD or KPTI?

Do analysts recommend RLMD or KPTI?

Summary

How does Karyopharm Therapeutics compare to Aerovate Therapeutics?

Do insiders & institutionals hold more shares of KPTI or AVTE?

Which has more volatility and risk, KPTI or AVTE?

Does the media favor KPTI or AVTE?

Is KPTI or AVTE more profitable?

Do analysts prefer KPTI or AVTE?

Which has better earnings and valuation, KPTI or AVTE?

Summary

How does Karyopharm Therapeutics compare to Gyre Therapeutics?

Which has more risk and volatility, KPTI or GYRE?

Do analysts rate KPTI or GYRE?

Do institutionals and insiders believe in KPTI or GYRE?

Does the media refer more to KPTI or GYRE?

Which has preferable earnings and valuation, KPTI or GYRE?

Is KPTI or GYRE more profitable?

Summary

How does Karyopharm Therapeutics compare to Solid Biosciences?

Does the media prefer SLDB or KPTI?

Do institutionals & insiders believe in SLDB or KPTI?

Which has better valuation & earnings, SLDB or KPTI?

Is SLDB or KPTI more profitable?

Which has more volatility & risk, SLDB or KPTI?

Do analysts prefer SLDB or KPTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools